Delivery Order SPE2DR25D2101-SPE2DR26F47RX
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $1,916.10 to AmerisourceBergen Drug Corp for the supply of Creon DR 36,000 unit capsules (100 count) on January 12, 2026, with completion scheduled for January 13, 2026. This non-competitive delivery order utilizes firm fixed pricing and is being fulfilled from AmerisourceBergen's place of performance in Conshohocken, Pennsylvania. The award falls under AmerisourceBergen's parent company, Cencora, Inc., which holds a significant...
- The Defense Logistics Agency awarded a delivery order valued at $5,717.04 to AmerisourceBergen Drug Corp for 24,000-unit capsules of Creon (pancreatic enzyme replacement therapy) on October 27, 2025, with completion targeted for October 28, 2025. This non-set-aside, competitively awarded contract utilizes firm fixed pricing and represents a routine pharmaceutical procurement to support federal medical supply needs. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered...
- The Defense Logistics Agency awarded a delivery order valued at $1,860.27 to AmerisourceBergen Drug Corp for 36,000 unit capsules of Creon (pancrelipase) in 100-count bottles. This competitive, firm fixed-price delivery order, with an ultimate completion date of September 11, 2025, represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026. The order will be fulfilled from the...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on January 14, 2026, for the supply of 36,000 unit capsules of Creon (pancreatic enzyme supplement) in 100-count bottles, with a ceiling value of $1,452.16 and a completion date of January 15, 2026. This is a firm fixed-price, non-set-aside competitive award issued under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December...
- The Defense Logistics Agency awarded a delivery order valued at $15,277.83 to AmerisourceBergen Drug Corp for 36,000 unit capsules of Creon (pancrelipase) in 100-count packages. This is a firm fixed-price, non-set-aside contract with a completion date of January 16, 2026, issued on January 15, 2026. The work will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 10, 2025, for 36,000 unit capsules of Creon (pancreatic enzyme replacement therapy) in 100-count packaging, valued at $2,254.12. This is a firm fixed-price delivery order with no set-aside designation, issued under the company's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a comprehensive $999.99 billion global pharmaceutical support vehicle running through December...
- The Defense Logistics Agency awarded a delivery order valued at $5,220.99 to AmerisourceBergen Drug Corp for 36,000 unit capsules of Creon (pancreatic enzyme replacement therapy) on January 22, 2026, with an ultimate completion date of January 23, 2026. The award was made on a firm fixed-price basis without set-aside designation, indicating competitive award to this major pharmaceutical distributor. The place of performance is listed as Conshohocken, Pennsylvania, which serves as the company's...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for 36,000 unit capsules of Creon (pancreatic enzyme replacement therapy) in 100-count bottles, valued at $1,860.18. The contract is a firm fixed-price delivery order with an ultimate completion date of July 7, 2025, and was awarded on July 3, 2025 without a set-aside designation. Performance will be executed from AmerisourceBergen's facility in Conshohocken, Pennsylvania. This delivery order is issued under...
- The Defense Logistics Agency awarded a delivery order valued at $27,202.55 to AmerisourceBergen Drug Corp for 36,000 unit capsules of Creon (pancreatic enzyme replacement therapy) on January 7, 2026, with an ultimate completion date of January 8, 2026. This is a firm fixed-price, competitively awarded contract with no set-aside designation. The order will be fulfilled from the vendor's location in Conshohocken, Pennsylvania. AmerisourceBergen Drug Corp operates as a subsidiary of Cencora,...
- The Defense Logistics Agency awarded a delivery order valued at $70,439.09 to AmerisourceBergen Drug Corp for 36,000 unit capsules of Creon (pancreatic enzyme supplement) in 100-count bottles. The contract, which was competitively awarded with no set-aside designation, carries a firm fixed price and an ultimate completion date of September 3, 2025. AmerisourceBergen will perform this delivery order from its corporate office location in Conshohocken, Pennsylvania, where the company maintains...
- SPE2DR25D2101Indefinite Delivery Contract
- SPE2DR25D2101-SPE2DR26F47RXDelivery Order
The Defense Logistics Agency awarded a delivery order valued at $1,629.96 to AmerisourceBergen Drug Corp for 12,000 unit capsules of Creon (pancreatic enzyme replacement therapy) on January 23, 2026, with an ultimate completion date of January 26, 2026. This firm fixed-price, competitively awarded contract—which carries no set-aside designation—will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. The award represents a child contract under a larger Indefinite Delivery Contract vehicle between DLA Troop Support Medical and AmerisourceBergen's parent company, Cencora, Inc., valued at $999,999,999.00 through December 2031. AmerisourceBergen Drug Corp is a major pharmaceutical distributor providing critical medical supplies to military and veteran healthcare systems through DLA's comprehensive global pharmaceutical support program. The company's extensive federal contracting history demonstrates its capability to deliver a broad spectrum of pharmaceutical products across multiple therapeutic domains, including specialty medications, brand-name and generic drugs, and medical devices. This particular delivery order for Creon supports the medical supply needs of Department of Defense healthcare facilities and aligns with DLA's ongoing mission to ensure pharmaceutical availability across military treatment facilities worldwide.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $1.6k | 1/22/26 |